The Application Value of Spectral CT in the Accurate Staging of Gastric Cancer

NCT ID: NCT06977386

Last Updated: 2025-05-18

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

NOT_YET_RECRUITING

Clinical Phase

NA

Total Enrollment

150 participants

Study Classification

INTERVENTIONAL

Study Start Date

2025-06-01

Study Completion Date

2026-05-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Spectral CT was used to prospectively collect medical images and clinical data related to gastric cancer, evaluate the effect of image quality in the diagnosis of gastric cancer, and evaluate the application value in the accurate staging of gastric cancer, so as to provide a more accurate clinical basis for diagnosis, promote the development of individualized treatment, and ultimately improve the prognosis of patients.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Gastric Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

DIAGNOSTIC

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

The application value of spectral CT in the accurate staging of gastric cancer

Prospectively collect medical images and clinical data related to gastric cancer using Philips Quark CT equipment, and evaluate the diagnostic accuracy and clinical application value in the accurate staging of gastric cancer.Patients diagnosed with gastric cancer in Yunnan Provincial Cancer Hospital from April 2025 to May 2026 were consecutively included, and after scanning with Philips Quark CT, the TNM stage of gastric cancer patients was assessed by two radiologists, and finally statistical analysis was performed.

Group Type EXPERIMENTAL

To explore the value of spectral CT in the diagnosis and treatment of gastric cancer

Intervention Type DIAGNOSTIC_TEST

CT scan of the abdomen outside of standard treatment options

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

To explore the value of spectral CT in the diagnosis and treatment of gastric cancer

CT scan of the abdomen outside of standard treatment options

Intervention Type DIAGNOSTIC_TEST

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* (a)Patients with pathologically confirmed gastric cancer;
* (b) aged ≥ 18 years old;
* (c) have not received chemoradiotherapy or surgery.

Exclusion Criteria

* (a)Combined with other primary tumors;
* (b) The image quality does not meet the diagnostic criteria;
* (c)Those who cannot tolerate CT examination.
Minimum Eligible Age

18 Years

Maximum Eligible Age

80 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

Yunnan Cancer Hospital

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

Responsibility Role SPONSOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Lianhua Ye

Role: STUDY_DIRECTOR

Ethics Committee of Yunnan Provincial Cancer Hospital

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Yunnan Cancer Hospital

Kunming, Yunnan, China

Site Status

Countries

Review the countries where the study has at least one active or historical site.

China

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Ruiling Yang

Role: CONTACT

17390212095

zhenhui Li

Role: CONTACT

13698736132

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

ruiling yang

Role: primary

+8617390212095

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

KYLX2025-102

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.